Device · Diagnostics · Digital Health

The Brief

March 2026 · Medtech Edition

Hey everyone 👋 Welcome to this week's roundup of device, diagnostics, and digital health news. Two weeks' worth of news this time, and there was A LOT. The surgical robotics space is getting crowded fast, structural heart had a monster run of approvals and data readouts, and Abbott dropped $21B to swallow Exact Sciences. Meanwhile, AI keeps showing up everywhere — from voice-based heart failure detection to telerobotic stroke procedures over 120 miles. Twelve notable funding rounds, a major cyberattack on Stryker, and the FTC blocking yet another Alcon deal. Let's get into it.

— Saranya

Top Headlines

Abbott closes its $21B Exact Sciences deal

What happened

The acquisition brings Exact Sciences' cancer diagnostics portfolio into Abbott, including Cologuard for noninvasive colorectal cancer screening and Oncotype DX for treatment guidance in early-stage breast cancer. For Abbott, which has traditionally been strongest in areas like medical devices, diagnostics, nutrition, and established medicines, the deal adds a meaningful oncology platform tied to earlier and more accurate cancer detection.

Why it matters

This is bigger than a normal medtech acquisition. Abbott is trying to own more of the cancer testing workflow, from screening to precision oncology.

Surgical robotics competition is starting to look real

What happened

CMR Surgical said its Versius robot has now been used in more than 45,000 patients globally and is preparing for its U.S. debut, while also contributing nearly 500 hours of surgical data to NVIDIA's Open-H initiative. XCath reported the first telerobotic stroke procedure over 120 miles, and Distalmotion is targeting ambulatory surgery centers with its Dexter robot priced at under $2 million. Revolve Surgical also picked up FDA 510(k) clearance for a compact, table-mounted surgical robot.

Why it matters

Intuitive Surgical is still the leader, but challengers are coming from multiple angles: lower prices, smaller systems, outpatient settings, remote procedures, and AI-enabled platforms.

Structural heart had a huge two weeks

What happened

JenaValve won FDA approval for Trilogy, the first transcatheter valve approved in the U.S. specifically for severe aortic regurgitation in high-risk patients. Abbott said its TriClip cut heart-failure hospitalization risk by 48%, Boston Scientific said Watchman FLX reduced non-procedural bleeding by 45% versus blood thinners with 99% procedural success, and Edwards shared two-year data showing durable benefit for Evoque in tricuspid regurgitation.

Why it matters

Structural heart is no longer just about incremental device updates. Companies are now winning with new indications, better outcomes data, and less invasive options for harder-to-treat patients.

GE just escalated the photon-counting CT race

What happened

GE HealthCare received FDA 510(k) clearance for Photonova Spectra, its photon-counting CT platform built on "deep silicon" detector technology. GE says the system offers ultra-high-definition imaging, faster acquisition, and better tissue characterization across neurology, oncology, and cardiology use cases.

Why it matters

Photon-counting CT is one of the most important imaging upgrades in years. This gives GE a more direct answer to Siemens in a premium imaging category that could reshape future CT buying.

Stryker's cyberattack became a medtech wake-up call

What happened

Stryker said a March 11 cyberattack disrupted manufacturing, shipping, and order processing across 79 countries, and reports tied to the incident said more than 200,000 systems were wiped. The company said no patient, customer, or supplier data was compromised, and that most core operations have since been restored.

Why it matters

This was not just an IT issue. It showed how quickly a cyberattack can spill into supply-chain disruption and real operational risk for a global medtech company.

Other News

Dexcom keeps widening the diabetes market. Dexcom shared G7 data at ATTD 2026 showing A1C reduction and weight-management benefits in type 2 diabetes patients not using insulin, and said G7 will fully replace G6 by July 2026. It also introduced Smart Basal, a basal insulin optimizer.

Cognito gave Alzheimer's medtech one of its strongest signals in a while. Cognito raised $105 million for Spectris, its non-invasive gamma-frequency stimulation platform, and shared OVERTURE data showing slowed brain-volume loss and improved brain activity. It also partnered with Ochsner to build real-world evidence and new care models around cognitive decline.

Endogenex posted some of the most interesting metabolic data of the month. Its ReCET system showed a 1.5% HbA1c reduction and 5.4 kg of weight loss at 48 weeks, then the company added a $50 million Series C extension to support pivotal studies and FDA work.

Hyperfine added more fuel to portable imaging. The company secured a $40 million loan facility to support commercialization of Swoop, the first FDA-cleared portable brain MRI, which is designed for bedside imaging in settings like ICUs and emergency departments.

AI diagnostics kept getting narrower and more practical. Anumana received FDA 510(k) clearance for its ECG-AI pulmonary hypertension detection tool, while Butterfly Network cleared an AI tool that estimates gestational age in under two minutes.

Alcon lost another deal. Alcon and Lensar terminated their $356 million merger agreement after the FTC signaled it would block the transaction, and Lensar will keep a $10 million deposit.

💰 Money Moves

That's it for this edition. If this was useful, forward it to someone who's building in medtech.

— The Device, Diagnostics & Digital Health Brief